询 单
请 填 写 相 关 信 息
产品信息
产品名称
别名
CAS号
结构式 上传
联系方式
公司
联系人
电话
邮箱
内容
提交
中文版 English
请输入产品名称、CAS式、分子式

Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting

来源:
发布时间:2021-11-09
阅读量:738

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the company’s lead immuno-oncology program, E-602, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.

Palleon’s poster highlights recent preclinical data from in vitro and in vivo studies of the company’s most advanced therapeutic candidate, E-602 (formerly known as Bi-Sialidase). E-602 is part of the company’s novel cancer immunotherapy platform, EAGLE (Enzyme-Antibody Glycan-Ligand Editing), which utilizes engineered human sialidase to degrade immunosuppressive sialoglycans.

In addition to the poster presentation, Palleon will be hosting a hybrid (live and virtual) scientific symposium at SITC on November 11th featuring Palleon Scientific Co-Founder Carolyn Bertozzi, Ph.D., Scientific Advisor James Paulson, Ph.D., and Chief Medical Officer David Feltquate, M.D., Ph.D. The session will review the most recent state of the science of sialoglycan-mediated immune regulation and its potential relevance for immuno-oncology therapeutics. To learn more and register to attend, visit this link.

“We’re looking forward to sharing more about the development of our EAGLE platform and the lead program E-602, which we believe is a uniquely powerful way to reverse the immunosuppressive effect of cell-surface sialoglycans,” said Li Peng, Ph.D., Chief Scientific Officer. “These data will inform our upcoming Phase 1 clinical trial of E-602, as well as our growing pipeline of EAGLE therapeutic candidates in oncology.”
 

上一篇: Janssen Licenses "Flexible Antibody" Technology from F-star in New Collab
下一篇: Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818
相关标签

最新资讯

相关产品

热门标签
询 单
请 填 写 相 关 信 息
产品信息
产品名称
别名
CAS号
结构式 上传
联系方式
公司
联系人
电话
邮箱
内容
提交
  • 请填写产品名称!
  • CAS号
  • 请正确填写公司名称!
  • 请正确填写联系人!
  • 请正确填写联系电话!
  • 请正确填写联系邮箱!
  • 请描述您的问题!